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Abstract: Due to the global emergence of antibiotic resistance, there has been an increase in research
surrounding endolysins as an alternative therapeutic. Endolysins are phage-encoded enzymes,
utilized by mature phage virions to hydrolyze the cell wall from within. There is significant evidence
that proves the ability of endolysins to degrade the peptidoglycan externally without the assistance
of phage. Thus, their incorporation in therapeutic strategies has opened new options for therapeutic
application against bacterial infections in the human and veterinary sectors, as well as within
the agricultural and biotechnology sectors. While endolysins show promising results within the
laboratory, it is important to document their resistance, safety, and immunogenicity for in-vivo
application. This review aims to provide new insights into the synergy between endolysins and
antibiotics, as well as the formulation of endolysins. Thus, it provides crucial information for clinical
trials involving endolysins.
Keywords: endolysin; antibiotic resistance; bacteriophages
1. Introduction
Endolysins are gaining importance in recent years due to their broad lytic activities
against Gram-positive and Gram-negative bacterial cells [1,2]. Endolysins are bacteriophage-
encoded enzymes, which act by hydrolyzing the host cell wall and subsequently allowing
the release of bacteriophage progenies. Therefore, such enzymes are essential components
of the lytic phage life cycle and are a promising alternative to antibiotics [1,2]. The lytic
activity of endolysins is classified into different types, namely; (a) acetylmuramidases,
(b) transglycosylases, (c) glucosaminidases, (d) amidases, and (e) endopeptidases [1,3].
These five different types are further explained in this review to emphasize their mode
of action, as well as regulation of expression. As mentioned, endolysins are involved in
peptidoglycan degradation during cell lysis, which is regulated by different phage lytic
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enzymes and holins [4]. Holins are small hydrophobic hole-forming proteins (>100 nm in
diameter) [4–8]. Notably, besides a few exceptions such as lysozyme or lysostaphin, phage
proteins rarely develop resistance among their bacterial hosts, mostly due to the horizontal
gene transfer among phage–host systems over a long time [1]. However, bacterial hosts
additionally develop resistance mechanisms against free endolysins such as development
of the outer membrane (capsule), exopolysaccharides (biofilms), etc. In a similar realm, the
host immune system such as pro-inflammatory cytokines and antibodies may have impli-
cations in the use of endolysin; both aspects will be discussed in further detail throughout
this review.
The research surrounding phage lytic enzymes as an alternative for antibiotic resis-
tance has rapidly increased. However, due to the lack of in-vivo studies and sufficient
clinical trials, the use of bacteriophages and endolysins for the development of an effective
phage therapy has been hindered [3]. Considering the recent progress in this field, our
review aims to corroborate the research and applicability of phage endolysins for in-vivo
therapies. It aims to provide information to continue advancing endolysin research. It
also highlights the importance of phage lytic enzymes as an effective alternative against
antibiotic-resistant pathogens and discusses their challenges and limitations.
2. History of Endolysins
The knowledge that phage lysates contain enzymatic activity that could cause in vitro
lysis of bacteria was initially documented by Frederick W. Twort during his discovery of
bacteriophages [9]. Twort noted in his seminal manuscript what was perhaps the first
evidence of endolysins, stating that there appeared to be a non-transmissible, heat-labile
property that produced transparent zones of lysis [9]. We now attribute this to either
endolysins or virion-associated peptidoglycan hydrolases (VAPGHs) of the staphylococcal
phage [10]. Importantly, endolysins, are different from virion-associated peptidoglycan
hydrolases (VAPGHs) as endolysins are secreted at the end of the phage lytic cycle [2]. In
contrast, VAPGHs are released from phage tail tips at the initial stage of peptidoglycan
penetration [3]. Twort later defined a “transmissible virus” (bacteriophages) as only acting
on live bacteria, whereas a non-transmissible “bacterial lysin” secreted by the virus would
act on dead bacteria [11]. To accompany this theory, dead staphylococci could not be
lysed by phage unless a small amount of live staphylococci was added, which released
some emerging agents [11]. By 1926, phage biologist F. D. Reynals confirmed Twort’s lytic
findings by performing identical experiments on both Gram-positive and Gram-negative
species, and noting that it was specific only to Gram-positive species [12].
By 1934, Alice Evans proceeded to classify bacterial strains using phage, founding
the analytical field of phage typing [13]. W. R. Maxted later launched an investigation on
the cause of nascent lysis reported by Evans and obtained a lytic factor from the phage
filtrates to establish its origin and role in the phage lytic system [14]. By 1957, Richard
Krause renamed the Evans B563 phage to C1 due to its defined specificity for Group C
streptococci. Krause became the first scientist to partially purify the C1 lysin [1]. Vincent
Fischetti, in 1971, prepared a highly purified C1 lysin as a resolution of his thesis work
at the McCarthy laboratory and this allowed for further detailed studies on how surface
proteins of Gram-positive organisms bind to the cell wall [1].
The term “Endolysin” was later published to represent “any one of several unrelated
types of enzymes (i.e., muramidase, amidase, or transglycosylase), which attack either the
glycosidic bonds (i.e., muramidase and transglycosylases) or peptide bonds (i.e., amidases)
that confer mechanical rigidity on the peptidoglycan” [15]. The use of endolysins against
in-vivo bacterial infections was later implemented in the early 2000s. Nelson et al. pub-
lished the first report investigating the prophylactic use of endolysin C1 in an in-vivo model
against upper respiratory group A streptococci [16]. Subsequently, Loeffler et al. published
a novel article on the use of endolysin Cp-1 against pneumococcal bacteremia through
intravenous administration [16,17]. By 2013, clinical trials for endolysin use were approved,
including a phase I study to evaluate the safety of pharmacokinetics and pharmacodynam-
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ics of endolysin SAL-1 based drugs, designed to treat antibiotic-resistant staphylococcal
infections [18], and a later phase I/II study using engineered chimeric endolysin Staphefekt
(Micreos Human Health BV, The Netherlands)to target Staphylococcus aureus responsible
for atopic dermatitis (Staphefekt™, developed by Micreos, is the world’s first endolysin
available for human use on intact skin) [19,20] (Figure 1).
Figure 1. Timeline showing a brief history of endolysin research work.
3. Endolysin Structure and Mode of Action
The structure of endolysins is a factor determined by their origin. However, the major-
ity of endolysins (usually a molecular weight of 15–40 kDa) have a modular configuration,
while endolysins acting on Gram-negative bacteria have a simple globular configuration [3].
Modular endolysins are often characterized by the presence of one or two (multi-domain)
N-terminal enzymatically active domains (EADs) linked by a short, flexible linker region
to a C-terminal cell wall-binding domain (CBD). This configuration is common to Gram-
positive phages and mycobacteriophages [3]. The N-terminal enzymatically active domain
(EAD) of modular endolysins functions to cleave various specific peptidoglycan bonds
in the murein layer of the host bacterium, while the C-terminal cell wall-binding domain
(CBD) recognizes and binds to different epitopes in the cell wall for proper fixation of
the catalytic effect of the EAD [21]. Endolysins from Gram-positive phages structurally
resemble fungal cellulases which are similarly constructed enzymes with EADs and CBD
joined by a flexible linker [22] (Figure 2a–c).
Endolysins of phages infecting Gram-negative host can be structured in various forms;
however, most are configured to have a simple globular module of the EAD (molecular
weight, 15–20 kDa) without a CBD [23] (Figure 2d,e). Recent studies also show the oc-
currence of Gram-negative phage endolysins with globular configuration, having one or
two CBDs at the N-terminal while the EAD module is toward the C-terminal [23]. Thus,
there is an inverted orientation of the general organization of common endolysins from
phages infecting Gram-positive hosts. There are also signal-arrest-release (SAR) Gram-
negative phage endolysins which are independent of holin-mediated endolysins [24]. SAR
endolysins are initially localized to the periplasmic membrane before further release from
the membrane to initiate host lysis. Endolysins of Phage P1 and ERA103, LyzP1 and Lyz103
respectively, are common examples [24,25].
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Figure 2. Modular configuration models of common phage endolysins. (a) Model with one N-terminal enzymatically active
domain (EAD) and a C-terminal cell wall-binding domain (CBD). (b) Multi-domain model with two EADs and a C-terminal
CBD. (c) Multi-domain model with a CBD located between two EADs. (d) Modular endolysin with a C-terminal EAD and
an N-terminal CBD. (e) Simple globular model of an EAD with no CBD. (f) Model of a tethered signal-arrest-release (SAR)
endolysin localized to the periplasmic membrane before release and activation of lysis function [24].
Based on the mode of action and individual enzymatic specificities, EADs are catego-
rized into three classes of six distinct enzymatic activities (Figure 3):
(a) Glycosidases generally cleave the β-1,4 glycosidic bonds linking alternating poly-
meric structures of N-acetylmuramic acids (MurNAc) and N-acetylglucosamines
(GlcNAc) in the peptidoglycan layer. Subclasses of Glycosidases include N-acetyl-
β-D-muramidases, which cleave bonds between MurNAc and GlcNAc; N-acetyl-β-
D-glucosidases, which cleave bonds between GlcNAc and MurNAc residues; and
lytic transglycosylases, which are not considered as true hydrolases as they do not
require water molecules for their catalytic action [21]. Like the other two glycosidases,
transglycosylases cleave β-1,4 bonds between MurNAc and GlcNAc, but also involve
an intra-molecular reaction that results in the generation of a 1,6-anhydro ring at the
MurNAc residue [26,27].
(b) Amidases, as N-acetylmuramoyl-L-alanine amidase, catalyze the cleavage of amide
bonds between the MurNAc and the first amino acid in the peptide stem
moiety, L-alanine.
Antibiotics 2021, 10, 124 5 of 29
(c) Endopeptidases cleave bonds between two amino acids of the stem peptide. Bond
cleavage can either occur within interpeptide bridge or stem peptide–interpeptide
bridge [27]. Examples include L-alanoyl-D-glutamate endopeptidase (VANY), c-D-
glutamyl-m-diaminopimelic (DAP) acid peptidase, D-Ala-m-DAP endopeptidase,
D-alanyl-glycyl endopeptidase (CHAP), etc. [28,29].
Figure 3. Schematic representation of the basic structure of bacterial cell wall peptidoglycan with possible catalytic activities
of endolysins indicated. A sub-class of Glycosidases, N-acetyl-β-D-muramidases cleave the β-1,4 bonds between NAM
(N-acetylmuramic acid) and NAG (N-acetylglucosamines), and N-acetyl-β-D-glucosidases cleave the β-1,4 bonds between
NAG and NAM residues. N-acetylmuramoyl-L-alanine amidases which are amidases cleave the amide bonds between
NAM and L-alanine. Endopeptidases cleave interpeptide and stem peptide–interpeptide bridges.
As the name suggests, the CBD binds to cell wall components such as the murein
ligands or secondary cell wall polymers: teichoic acids and natural polysaccharides of the
bacterium [30]. PlyG and PlyL (amidases) are endolysins binding selectively to secondary
cell wall polysaccharides of the bacilli cell wall [31]. A probable hypothesis for the presence
of the CBD motifs in most Gram-positive phage endolysins is that the binding of this
domain to ligands of the peptidoglycan layer conserves the diffusion of endolysins and the
destruction of nearby potential hosts after cell lysis is achieved, hence, allowing progeny
phages to carry out novel infection stage [3]. The presence of the outer membrane barrier
shielding the peptidoglycan layer of Gram-negative bacteria would discourage expulsed
endolysins from gaining access to neighboring cells at the end of the lytic cycle.
To overcome the outer thick mycolate layer linked to the peptidoglycan layer in
mycobacteria, the mycobacteriophages have evolved two forms of EAD lysins; Lysin A,
Antibiotics 2021, 10, 124 6 of 29
the peptidoglycan hydrolase and Lysin B, the mycolyl arabinogalactan esterase, cleaving
bonds between the mycolic acid and the arabinogalactan [28,32].
The structure of a tailed phage consists of two parts: the icosahedral head which
contains and protects the phage genome and the tail, which attaches to the specific receptor
site on the bacterial cell wall. Bacteriophage injects its DNA into bacteria via its tail, and a
progeny phage is produced. These newly produced phages go on to lyse bacterial cells [33].
The release of phage progeny at the end of the lytic cycle is facilitated by holins and lysins.
Within the bacterial host cell at the late stage of phage lytic cycle, holin is produced, which
makes a hole in the bacterial cytoplasmic membrane and creates a channel to facilitate lysin
delivery to the bacterial peptidoglycan, which results in cleavage of specific peptidoglycan
bonds and disrupts the bacterial structure (Figure 4) [4].
Figure 4. Mechanism of action of endolysin.
Basically, there is a three-step model system of the bacterial host lysis. This model
consists of three proteins named endolysin, holin, and spanin. These proteins perform
actions on the bacterial outer membrane, inner membrane, and peptidoglycan and can
cause the lysis of the host. There are two distinct mechanisms for the degradation of
the peptidoglycan in Caudo-virales of Gram-negative hosts: (1) Holin–endolysin and
(2) Pinholin SAR endolysin. In the prior step, the degradation of the peptidoglycan is
initiated when holin makes small pores in the host inner membrane; then, lysis is initiated
by releasing endolysin inside the periplasm and degrading the peptidoglycan. In the last
step, lysis is started when the pinholin can perform the membrane depolarization which
can activate the secreted SAR endolysin. Previously it was thought that for the lysis of the
Gram-negative hosts the degradation of the first two barriers of the membrane is sufficient,
but according to the new findings, spanin, which is another lysis protein, is required for
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the degradation of the outer membrane. The lysis of the bacterial host cell occurs through
this mechanism [34].
Multiple in-vivo experiments have shown that endolysins are effective against a variety
of Gram-positive bacteria such as PlyC [35], C1 [36], ClyR [37], Cpl-1 [38], ClyV [39], and
ClyJ [40]. Phage endolysins often show robust antibacterial activity against Gram-positive
bacteria but compromised activity against Gram-negative bacteria due to the presence
of protective outer membrane [41–43]. However, in recent years molecular engineering
approaches have increased the applicability of endolysins in targeting Gram-negative
pathogens [44].
The peptidoglycan disruption by endolysins results in destruction of bacterial cells
and the cell hydrolyzing phenomenon can be detected by a variety of enzyme assays.
The enzyme activity can be detected based on clearing of bacterial suspension, native
peptidoglycan degradation, a formation of a clear zone within the peptidoglycan matrix or
bacteria, and a decrease in viable cell count in terms of cell forming units [45]. The endolysin
enzymatic activity is commonly quantified in presence of tris or phosphate buffers, which
provide an optimal environment for its lytic activity. The enzyme activity can be monitored
by observing a corresponding reduction in the optical density of bacterial suspension at
600 nm at 37 ◦C [17,46]. Zymogram or overlay assay is a deviation of turbidity reduction
assay, in which the peptidoglycan of bacteria mixed with a semi-solid matrix is cleared as
compared to the liquid bacterial suspension. Overlay assays can be used for the purpose
of screening large endolysin-expressing libraries while zymograms show the hydrolytic
activity of endolysins on SDS-PAGE at a specific spot, which corresponds to their molecular
weight [47–49]. The reduction in the colony-forming unit (CFU) is another commonly used
method for quantifying bacterial reduction over a time of endolysin treatment [50]. For
visible enzyme activity, spot assay is commonly practiced in which lawn of host bacterial
cells are spotted with a small volume of 5–10 µL enzyme suspension. The minimum amount
of endolysin which shows clear bacterial cell lysis is defined as the “minimum inhibitory
concentration” of that endolysin [30]. Until now, most of the characterized endolysins
showed good bactericidal activity ranging from 102–108 units/mg of the enzyme [51].
4. Regulation of Expression
Bacteriophages are dependent on their bacterial hosts, as the lytic and lysogenic life
cycles are intervened with at the genetic level by utilizing host genetic machinery [1,52,53].
Considering the importance of the bacterial host in the regulation of phage enzyme ex-
pression, it is necessary for phages to hijack host genetic machinery for their progeny
generation, as well as their liberation through host cell by the production of endolysins.
Hence, it is necessary to understand how the phage genome regulates the expression of
different phage enzymes during their lytic life cycle [1,52]. Endolysins and holins are an
important group of phage lytic proteins that mediate the two critical processes during
phage life cycle, namely “lysis from within” (phage releasing from host cell) and “lysis from
without” (endolysin present on some phage surface lyse host cell) [54,55]. The regulation of
phage lytic proteins like holins, VAPGHs, and endolysins (lytic genes transcription) occurs
during the different stages of phage life cycle and is maintained until the end. The lytic
enzymes are produced to release the phage progeny from the host cell, which is reported
from the different experiments carried out with different phages [56–60]. The transcriptions
of endolysin are carried out by host transcription factors [61,62] and post-translational
regulation of endolysins is also reported, where holin-mediated transport or mechanisms
not yet fully understood are involved in endolysin transportation in the inactive form,
which later becomes active after protein conformational changes [52].
The regulation of expression of phage lytic enzymes in Lambda phage (λ phage)
explains the mechanism by which its lytic and lysogenic life cycle are controlled by Cro
and cI proteins [63,64]. For the phages to undergo the lytic cycle, the transcription of
Cro gene to produce Cro protein is essential. For the Cro protein to express, the absence
of cI protein is crucial. Whereas, for the lysogenic cycle, the transcription of cI gene to
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produce cI protein is essential, and for this protein to express, the absence of Cro protein
is decisive [63,64]. The nutritional condition of the host cell also determines the lytic or
lysogenic decision [53]. In the presence of nutrients, a lytic state is established and phage
progenies are released, whereas the absence of nutrients leads to a lysogenic conversion [53].
The initial regulation of Cro protein is essential for the expression of different lytic genes,
which also involves phage lytic proteins such as endolysins, holins, and virion-associated
peptidoglycan hydrolases (VAPGHs) [65]
However, in lytic phages, expression of endolysins and lytic proteins are independent
of Cro gene making them effective for phage therapy [63–66]. On the contrary, it is
interesting to know that, unlike lytic phages, lysogenic phages integrate their genetic
material in the host genome and multiply with the host genome until they undergo lytic
conversion [56–60]. This suggests that the evolution of phage lytic enzymes and proteins is
more frequent in lysogenic phages rather than lytic phages, as the latter lack the essential
enzymes required for horizontal gene transfer and end up degrading the infected host
genome following lytic activity [63–66].
5. Endolysins as Antibacterial Agent
Since the discovery of bacterial viruses, known as bacteriophages, their lytic enzymes
(endolysins) have also received significant attention, particularly for their potential as an
alternative therapeutic against bacterial infections in animals and humans [67].
5.1. Human Medicine
Due to the reduction in antibiotics efficacy, many infectious pathogens have become
life-threatening agents in humans. Therefore, to combat this issue, research has focused on
phage-derived endolysins for both topical and systemic infections in humans [68].
The human skin is a natural barrier to prevent microbial infections; however, dis-
ruption of the epithelial barrier (e.g., cuts, burns, wounds, etc.) may result in infections
caused by both Gram-negative and Gram-positive species [69,70]. One particular Gram-
positive pathogen that has received significant focus is S. aureus, due to its involvement
in topical skin or tissue infections, as well as systemic blood poisoning, bone, and car-
diac infections [71]. Furthermore, the rise in multidrug-resistant (MDR) and methicillin-
resistant S. aureus (MRSA) has reduced the availability of effective therapeutics. Therefore,
recombinant endolysins have become a novel treatment, paramount to controlling S. aureus
super-bugs in clinical or hospital sectors. For example, commercially available recombinant
endolysin, Staphefekt SA.100, and XDR.300 (Micreos Human Health BV, The Netherlands)
have been implemented in patients with chronic skin disease caused by S. aureus [72]. The
administration of Staphefekt has been advised in the presence of signs and symptoms
of inflammation for most of the skin infections including rosacea, acne, and eczema [73].
Another endolysin, CHAPK, has the potential to reduce S. aureus colonization in the skin;
therefore, this novel endolysin is used as a disinfecting agent in healthcare sectors [74].
S. aureus has also been considered as a major problem in nasal infections. S. aureus is
the causative agent in up to 30% of human nasal infections worldwide [75]. Phage endolysin
P128 has been formulated into a hydrogel and in vitro assays show this formulation can
successfully lyse clinical Staphylococcal isolates collected from the human nostrils [76].
However, unfortunately, endolysins have not yet been permitted for use in reducing
S. aureus contamination in the human nasal cavity and are awaiting clinical trials [77].
In contrast, Gram-negative pathogens such as Acinetobacter baumannii and
Pseudomonas aeruginosa have been considered major opportunistic pathogens in burn
wounds [78]. To combat such drug-resistant pathogens, novel engineered endolysin named
artilysins have been suggested as suitable alternative agents (Artilysin® is a registered
trademark in the European Union, United States, and other countries). In 2014, Briers and
their research team have successfully evaluated novel endolysin LoGT-008 activity with
minimum inhibitory concentration against P. aeruginosa and A. baumannii responsible for
skin infections [79]. The developed human neonatal keratin epidermal cell line model was
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challenged with P. aeruginosa, followed by administration of LoGT-008 and a wild type
endolysin PVP-SE1gp146. Results showed that both endolysin components could protect
the human cell line (100%) from P. aeruginosa infections via the rescue of the cell line and
reduced bacterial numbers [79].
Phage-derived antimicrobial compounds have been successfully applied against most
of the Gram-positive pathogenic infections. Recent studies have revealed the efficiency
of phage lysins against S. aureus pathogen using animal experiments and human clinical
cases [80]. Interestingly, phage endolysins are applied in various human clinical trials
right now. For instance, endolysin SAL200 and CF-301 have been successfully developed
against S. aureus for the treatment of bloodstream and cardiac infections [67]. A decade
ago, Cheng and Fischetti addressed the phage muralytic enzyme, PlyGBS, with weak lytic
activity compared to its mutant PlyGBS90-1 with hyperthymic activity. Research proved
that the population of streptococci could be reduced by considerable numbers (28-fold)
using a phage muralytic enzyme mutant. Bacterial vaginosis is the best example of the
phage-derived protein approach. Moreover, this research team noticed that the mutant
PlyGBS90-1 has numerous benefits such as rabid, efficient lytic activity against streptococci
in mouse vaginal colonization model [49]. This new system with phage-derived lysins
would be a robust approach to declining antimicrobial resistance compared with phage
cocktail therapy (Figure 5).
Figure 5. The schematic diagram shows the lytic efficacy of bacteriophages and endolysins. (A) Bacterial strains getting
resistance against specific phage after phage therapy. (B) Phage endolysin therapy shows better killing efficiency than phage
cocktail therapy.
5.2. Veterinary Sector
Reports state that penicillins are the most prescribed antibiotics in the veterinary
sector [81,82]. Due to the misuse and overuse of antibiotics, we have seen the dramatic
evolution of bacterial resistance in aquaculture, agriculture, and veterinary medicine [83,84].
The transmission of antibiotic-resistance genes from contaminated food to humans and
vice versa has been extensively studied [85]. Particularly, food animals such as cattle,
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poultry, and swine have been found to be a major reservoir of antibiotic-resistant bacteria
and its specific gene that can move to people directly or indirectly by the food chain [86].
As a consequence, the use of antibiotics in animal feed has been banned in the United
States [84] and the European countries [87]. Therefore, there is a significant need for
antibiotic alternatives, such as endolysins, along with the preclinical studies of endolysins
for veterinary applications [88].
Phage-encoded endolysins have been recommended as an impressive agent to coun-
teract most farm animal-related pathogens such as Clostridium perfringens, Streptococcus suis,
Paenibacillus larvae, and Salmonella species [88]. The poultry industry has reported major is-
sues due to the emergence of Gram-positive antimicrobial-resistant pathogen C. perfringens,
which can cause infections in up to 95% of chickens [89]. In 2014, Tamai and their research
team have also performed and designed phage endolysin phiSM101, that has been utilized
in poultry with broad lytic activity against C. perfringens pathogen [90]. In that same year,
Gervasi and colleagues designed an amidase endolysin, CP25L, which harbored the ability
to reduce 50% of another Gram-positive pathogen Lactobacillus johnsonii within 24 h [91].
Similarly, salmonellosis is the major infection in poultry caused by Gram-negative pathogen
Salmonella that is also relatively common and results in economic losses in the poultry
industry [92]. In general, research proves that phage endolysin has the ability to defeat
antibiotic resistance and its problems in both Gram-positive and Gram-negative pathogens.
A deadly zoonotic disease, anthrax has the potential to infect farm animals and wild
animals as well as humans. Schuch and colleagues reported the advantages of amidase-
type endolysin PlyG isolated from gamma phage-type with significant therapeutic effect for
the control of Bacillus anthracis [93]. Despite such promising results, a few major challenges
should be considered for the application of endolysins in the veterinary area, particularly
cost and production efficacy. In recent studies, such challenges of endolysin have been
improved by the modern protein modification assay and algae-based endolysin synthesis
assay, respectively [94].
Streptococcus equi is the primary representative for upper respiratory tract inflamma-
tion in Equus caballus (horses) [68]. To control S. equi pathogen, Hoopes and colleagues
have explored the potential of amidase endolysin PlyC, which can broadly be used as
an antimicrobial agent with 1000-fold increase in efficacy compared to routinely used
disinfectants [95].
Canine pyoderma is one of the most common bacterial skin infections diagnosed in
dogs, which is generally caused by methicillin-resistant Staphylococcus pseudintermedius
(MRSP). An earlier clinical trial showed that dogs can recover from pyoderma with contin-
uous treatment with anti-staphylococcal protein P128 hydrogel [96]. In addition, chimeric
endolysins have been used with the combination of the cell wall-targeting domain of
bacteriocin and the muralytic domain of phage K to treat canis skin lesions [76].
Bovine mastitis is the most prominent and persistent disease in animal husbandry, and
three-quarters of bacterial infections are caused by Staphylococci and Streptococci species [97].
In previous studies, Schmelcher and colleagues demonstrated the synergistic effect of phage
lysins with lysostaphin to combat S. aureus in the murine animal model [30]. Over recent
years, pure endolysin Trx-SA1 of phage IME-SA1 has been used in the therapeutic trial
process to control clinical mastitis-caused MRSA [98]. Another notable zoonotic microbe,
Streptococcus suis, has been associated with pig-related diseases such as arthritis, septicemia,
meningitis, and endocarditis [68]. Surprisingly, Wang and colleagues have proved that
Streptococcus phage endolysin, LySMP, can recover diseased pigs from clinical S. suis in
China [99]. While the use of endolysins as an animal therapeutic is currently in its infancy,
such promising results pave the way for future research within this field.
5.3. Agriculture and Plants
The prevalence of antibiotic resistance in the food chain process within agriculture and
crop culture has led to the causes of bacterial infection in humans. For example, multidrug-
resistant leaf blight rice can cause nosocomial infections in humans with a weak immune
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system. Thus, phage-based endolysin therapy has been suggested to ensure the safety
of plants from pathogens. Two decades ago, transgenic tomato plants were successfully
produced with CMP1 phage endolysins to prevent infection of Clavibacter michiganensis,
a bacterial species responsible for bacterial canker [100]. Similarly, another team focused
on transgenic potato plants produced with T4 phage lysin that holds resistance against
the pathogen Erwinia carotovora [101]. A previous report revealed that the endolysin-based
defense system has significant potential to overcome antibiotic resistance with the design
of transgenic plants.
Apis (Honey bees) are significant insect pollinators of crops; however, they are com-
monly infected with Paenibacillus larvae, which causes sepsis and death [68]. To control the
emergence of resistance, Endolysin PlyV12 has potential with high lytic activity against
antibiotic-resistant Enterococcus faecium and Enterococcus faecalis [102].
5.4. Food and Biotechnology
5.4.1. Food
It is well known that food animals such as chicken, cattle, and pigs and their prod-
ucts are a source of drug-resistant pathogens [68]. To control the emergence of resis-
tance, Endolysin PlyV12 has potential with high lytic activity against antibiotic-resistant
Enterococcus faecium and Enterococcus faecalis [102]. Interestingly, plant-based milk is suscep-
tible to L. monocytogenes contamination; therefore, studies have shown excellent sterilization
efficiency in soya milk when LysZ5 is administered [103]. Additionally, L. monocytogenes
pathogen has successfully been treated with various alternate phage endolysins such as
PlyP825, PlyP40, and Ply511 in the presence of hydrostatic pressure [104].
Throughout this review, S. aureus has been highlighted as a pathogen in human and
animal medicine; however, this bacterium is also responsible for food and milk contam-
ination during the production process [68]. In a recent study, Chang et al. reported that
the existence of a cell wall binding domain in Staphylococcal endolysin, LysSA11, showed
excellent specificity and antimicrobial activity when compared to endolysin LysSA97 with
moderate activity against S. aureus [105]. Overall, phage endolysins have been raising
interest due to their various applications in food safety and food processing systems.
5.4.2. Biotechnology
Advanced biotechnological approaches such as genetic engineering and therapeu-
tic protein (endolysin) have the potential to improve the food safety process via rapidly
eradicating bacterial pathogens due to their enzymatic nature. To stop the prevalence of
antibiotic-resistant microbes that cause food-borne infections, phage endolysins have been
recognized as natural bio-preservatives in food sectors. During food production, it is neces-
sary to ensure safe and hygienic surfaces are maintained, in order to prevent foodborne
outbreaks within the community. Using peptidoglycan hydrolases and endolysins, biofilms
have been completely eradicated in food and clinical environments, ensuring sufficient
surface disinfection.
Bacterial biofilms’ associated problems can be overcome by engineered endolysin or
peptidoglycan hydrolases. For instance, engineered endolysin SAP-2 and LysSMP have
the potential to eliminate biofilms formed by Staphylococcus and Streptococcus species, two
important pathogens in food and clinical environments [106,107]. Biofilm matrix can be
directly lysed by endolysin; that happens due to its diffusion through the extracellular
material of pathogens. Moreover, endolysins have significantly been involved in develop-
ing vaccines. In this process, a phage endolysins-based surface display system has been
applied to lactic acid bacteria, specifically in food and medical applications [108].
Recombinant endolysin has been applied for the treatment of farm animals. For
instance, MRSA cell numbers have been effectively reduced when endolysin Trx-SA1 was
used as a therapeutic tool in cow udders. In addition, animal model study proved that
the combination of phage endolysins (2638A, 80a, LysK, lysostaphin, phi11, and WMY)
can provide complete protection from bacteremia-induced death when compared with
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single endolysin (phiSH2) therapy. It is clear that phage endolysin with biotechnological
approach can assure the control of future farm animal infections [65].
In the case of clinical trials, advanced techniques like extensive protein engineering
have enhanced phage endolysin activity against antibiotic-resistant Gram-positive and
Gram-negative pathogens. Furthermore, unique endolysin domain has been applied for
various purposes, for instance, immune-based therapeutic and diagnostic approaches [69].
Phage endolysin-based biotech companies such as GangaGen, ContraFect, and Micreos
have developed phage lytic proteins P128, CF-301, and Staphefekt against S. aureus, respec-
tively. Those endolysin products can successfully treat chronic kidney disease, bloodstream
infections, and skin infections [19,65]. Overall, phage endolysins have been considered to be
a promising approach to diagnosing and killing pathogenic populations in the most crucial
fields such as agriculture, human medicine, and veterinary medicine today (Figure 6).
Figure 6. Bacteriophage endolysins as an antibacterial agent. (A) Phage-derived endolysin protects humans, animals, plants
that are extremely infected with antibiotic-resistant pathogens and also inhibits the prevalence of antibiotic resistance via
other food chains. (B) Overuse of antibiotics in food chains and human and veterinary medicine causes uncontrollable
bacterial infections with multidrug resistance that leads to future pandemics.
6. Endolysin in Biofilms Eradication
Bacteria are universally found in nature attached to surfaces such as living tissues,
medical devices, industrial equipment, or food [109]. During attachment, some bacteria
produce extracellular polymeric substances (EPS) forming a complex cluster of bacterial
cells, known as biofilm [109]. This polymeric network mainly consists of exopolysaccha-
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rides as well as nucleic acids, proteins, and lipids, providing mechanical stability and
adhesion to surfaces [110]. The life cycle of the bacterial biofilm is shown in Figure 7.
Figure 7. Biofilm growth stages and degradation: (A) the stages of bacterial biofilm formation from the initial attachment
to mature biofilm formation, (B) the process of biofilm dispersal using phage endolysins and phage-derived enzymes as
agents of biofilm degradation and bacterial cell lysis.
In clinical and food settings, biofilms are major concerns as they form on critical
locations causing contamination that affects the efficacy of the established procedures; for
example, the bacterial colonization on the outer surfaces of catheters [111]. Moreover, they
cause treatment failure in surgeries and chronic wounds due to antibiotic-resistant bacteria
housed within the biofilm network [112].
EPS matrix reacts chemically with the antimicrobial agents and limits their diffusion
rate [113]. In addition to the EPS matrix protection, the biofilm cells change the surrounding
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environment to provide conditions that inactivate any antimicrobial agent and protect
the microbial communities within the biofilm network. Consequently, the development
of novel anti-biofilm techniques has been necessarily required to provide further control
strategies [111].
Lytic phages are used in phage-based therapies not only because they damage the bac-
terial hosts but also because they lack the essential enzymes for horizontal gene transfer [66].
Many characteristics should be taken into consideration during designing phage-based
methods to treat biofilms and bacterial infections such as the rate of phage diffusion, pen-
etration, and propagation [114]. Endolysins are very useful in biofilms treatment; their
use has shown significant results and their efficacy has been discussed in many studies.
Guo, M. et al. used the novel endolysin LysPA26 to eliminate Pseudomonas aeruginosa
in the biofilm formation [66]. LysPA26 could lyse other Gram-negative bacteria such as
Acinetobacter baumannii, Klebsiella pneumonia, and Escherichia coli under a broad range of
temperatures from 37 ◦C to 50 ◦C. Their study demonstrated that LysPA26 could degrade
the biofilm and disrupt the bacteria in a concentration-dependent manner; this was indi-
cated by a reduction in the biofilm optical density (OD600) [66]. Meng et al. experimented
with the effect of manufactured bacteriophage lysin, LySMP, to treat Streptococcus suis
biofilm alone and mixed with antibiotics and bacteriophage. They found that LySMP alone
could treat the biofilm with >80% removal, compared to <20% removal when the biofilm
was treated with bacteriophage alone and/or with antibiotics. The results demonstrated
that LySMP could act synergistically to treat S. suis biofilm in a concentration-independent
manner and inactivate the released cells [106].
In animal models, the engineered peptidoglycan hydrolase is used to cleave important
bonds in the peptidoglycan structure of S. aureus that increased the rate of bacterial colony
lysis and biofilm removal [115]. Recently, glycoside hydrolases show results to disturb
P. aeruginosa biofilms and encourage the killing of neutrophil-mediated communities [115].
In addition, fusion proteins that are derived from bacteriophage-encoded endolysins can
specifically reduce the resistance rate of bacterial communities in the biofilm without
targeting the commensal bacteria [116].
Persister cells are small subpopulations of bacterial cells that show high resistance
to antibiotics because of their ability to enter a dormant state when they are treated with
a bactericidal antibiotic that enables them to survive [117]. Therefore, persister cells are
one of the big issues in biofilm removal. In addition to their antibiotic resistance activity,
they can regenerate the population just after stress removal [118]. Gutiérrez et al. (2014)
used phage-derived lysin, LysH5, in biofilm removal to kill S. aureus persister cells; results
showed no persister cells remained in the Staphylococcal biofilm treated with 0.15 µM of
LysH5. There was also a complete inhibition in biofilm formation in select strains.
7. Immunogenicity, Safety, and Resistance
In the wake of the urgent need to develop alternatives to conventional antibiotics for
therapeutic use, bacteriophages have been considered as plausible alternatives. However,
their use as antimicrobial agents might be limited or totally hindered due to limitations
they pose which include: reduced activity due to immune system response, the possible
emergence of bacterial resistance against bacteriophages, and health safety issues [119].
While the myriad of limitations involved in the use of whole phage cause concerns, attention
is fast shifting to the use of phage endolysins. As promising as endolysins are in the fight
against antimicrobial resistance, their ultimate approval as therapeutics for the public is
highly hinged on these three factors; immunogenicity, which is how the immune system of
the body will respond to them, their safety profile on human health, and the possibility
of bacteria building resistance against endolysins. Such factors require clinical trials on
endolysins for a better insight into these concerns.
These factors and concerns are highly justifiable as most biopharmaceuticals are
known to induce immune responses; in some cases, the consequences can be severe and po-
tentially lethal, causing a loss of efficacy of the drug or even worse, leading to autoimmunity
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and hypersensitivity reactions. The body elicits an immune response against exogenous
protein products, a class to which phages and endolysins belong, by the activation of T cells
and the consequent production of neutralizing antibodies [120]. In fact, this effect has been
one of the limiting factors in the use of phages therapeutically [121,122]. Antibodies are
known to be poorly effective in endolysin inactivation; an example is seen in a study carried
out using Cpl-1 where the presence of antibodies sufficiently reduced the systemic half-life
of Cpl-1 to approximately 20 min [17]. The result of a study carried out using LysGH15
endolysin to test for the effect of endolysin inactivation by antibodies shows that LysGH15-
specific antibodies did not affect the killing efficiency of LysGH15 against MRSA in vitro
or in-vivo [123]. Similar studies conducted by other researchers have shown that this trait
is not specific to LysGH15. In a study conducted by Loeffler et al. [17], using endolysin
Cpl-1 on pneumococcal bacteremia, rabbit hyper-immune serum raised against Cpl-1 was
used to determine the effect of immunized serums on endolysin-bacterial lysis. The result
of the research showed that in non-immunized serum, 2000 µg of Cpl-1 decreased the
viable bacterial count in a pneumococcal solution from log109.2 to log106.2 CFU/mL within
1 min. However, when the same experiment was performed using hyper-immunized
serum (titer = 10,000), the bacterial titer decreased slightly less, to log107.0 CFU/mL. All
titers decreased another 0.5 log10 CFU/mL by 10 min; this indicated that high immune
serum decreased, but did not completely block the killing of S. pneumoniae by Cpl-1. Al-
though antibodies are known to be poorly effective in endolysin inactivation, their presence
sufficiently reduced the systemic half-life of Cpl-1 to approximately 20 min, indicating that
one or two doses of endolysin therapy might not be enough for complete eradication of
infections [17]. Concerning safety issues, the pre-clinical trials performed using animal
models have shown that endolysins have a good safety profile and showed no adverse
effects like fever, abdominal pain, or diarrhea, proving to be safe moving forward [67].
To support the safety of endolysins, SAL200 was administered intravenously to dogs
and monkeys, and no adverse effects were observed or reported in both animals [67,124,125].
The safety profile and tolerance of SAL200 endolysins were also evaluated in humans;
adverse effects reported in more than three participants were fatigue, rigors, headache, and
myalgia. Furthermore, no clinically significant values were recorded with respect to the
findings of clinical chemistry, hematology and coagulation analyses, urinalysis, vital signs,
ECG, and physical examinations [67].
Another study conducted to test the effect of LysGH15 on S. aureus in mice showed
that high-dose LysGH15 injection did not cause significant adverse effects or pathological
changes in the main organs of treated animals [123]. LysGH15 does not enhance IgE levels
among total serum antibodies. IgE activates mast cells and basophils, and these cells release
histamines and other chemical substances upon activation, an essential step during most
allergic reactions. Histological analysis of the study showed that neither repeated injections
nor large-dose infusions of LysGH15 resulted in inflammation or mast cell activation in
major organs in mice. The potential for an IgE response in humans should be investigated,
as this effect would trigger severe side effects such as hypersensitivity, allergic reactions,
and possibly cancers if extreme [123].
A study conducted by Jun et al. tested the effect of SAL200 endolysin on Staphylococcal
infections in humans. Results showed that the potential of developing resistance to SAL200
is significantly lower than that of conventional antibiotics [67]. The report further showed
that no mutants were resistant to SAL200 during its development. Repeated exposure of an
S. aureus strain to half of the minimum inhibitory concentration (MIC) of SAL200 30 times
failed to generate a resistant mutant [67].
This is indeed great news, as in response to phage, bacterial cells can evolve mecha-
nisms of resistance [126]. Such resistance tactics include modification of phage receptors on
the bacterial surface, secretion of substances that prevent phage adhesion to the bacterial
pathogen, activation of measures for blocking phage DNA injection into the cell, and inhibi-
tion of phage replication and release [126]. In fact, statistically, in all bacterial populations,
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such resistant mutants exist, and they can become prevalent due to the selective pressure
by bacteriophages during phage therapy [127].
8. The Effect of Endolysins on the Normal Microbiota
The human host is colonized with a large number of microbial cells as part of their
normal microbiota, covering different parts of the human body such as the urogenital
and gastrointestinal tracts, the nasal and oral cavities, and the skin surface [128]. It is
estimated that more than 100 trillion symbiotic microorganisms colonize human beings
and are of great significance to human health and illness [129]. The normal microbiota
forms a physical barrier to protect its host from foreign pathogens, through competitive
exclusion and antimicrobial production [130]. Any disturbance to the normal microbiota
may cause serious disease. For example, intestinal microbiota dysbiosis influences the
level of immune mediators’ production leading to metabolic dysfunction and chronic
inflammation [131]. Additionally, hepatitis B virus (HBV), human immunodeficiency virus
(HIV), and other diseases are associated with microbiota disturbance [131].
Even though antibiotics act to improve human health and life expectancy, broad-
spectrum antibiotics disrupt the existing microbiota, causing dysbiosis and leading to
disease outcomes [128]. Figure 8 shows the effect of microbiota disturbance on different
systems. In contrast to antibiotics, endolysins selectively treat specific species or subspecies
of pathogenic bacteria without causing disturbance to the surrounding normal micro-
biota [102], as previously reported by experiments on Enterococcus faecalis and E. faecium
using bacteriophage-induced lysin called PlyV12. Their results demonstrated that PlyV12
showed a great lytic effect on the vancomycin-resistant strains of E. faecalis and on multiple
strains of E. faecium. Therefore, lysins show less disruption of the normal microbiota when
they are used to treat various infections, as they do not transfer resistance genes or bacterial
toxins destroying the colonizing bacteria of mucous membranes [132]. They can induce the
response of the immune system without neutralizing or preventing antimicrobial activity.
Hence, they can be used for systemic infections treatments [133]. Additionally, lysins treat
the rapid lysis of Gram-positive bacteria through an exogenous application as recombinant
enzymes [132].
For instance, an enterococcal lysin is reported to kill enterococci and a number of other
Gram-positive bacteria, including S. aureus, S. pyogenes, and group B streptococci [102].
Despite their low activity toward these pathogens, this enterococcal lysin has been recorded
as one of the broadest acting lysins recognized [102]. Additionally, some naturally occurring
lysins have potent activity toward Gram-negative bacteria despite the structural barrier
and low permeability of their outer cell membrane to lysins. Ghose and Euler (2020) stated
that the addition of some stimulants increases the intrinsic bactericidal activity of lysins
significantly toward Gram-negative bacteria. For instance, the fusion protein called artilysin
that is composed of a lysine fused to destabilizing peptide is active against both Gram-
positive and Gram-negative bacteria. One example of artilysins is the broad-spectrum Art-
175 that is composed of P. aeruginosa lysin KZ144 modified version [79,134,135]. Therefore,
using lysins in infection control is recently of great importance for treating different specific
infectious diseases without causing serious harm to the normal microbiota [133]. Imanishi
and colleagues conducted experiments in-vivo and in vitro to examine the lethal effect of
the Kayvirus-derived endolysin on staphylococcal impetigo [136]. The results showed that the
enzyme could exhibit a bactericidal effect on S. aureus after 15 min incubation period and
reduced intra-epidermal staphylococci number and pustules size in the impetigo mouse.
Additionally, the treatment with lysin increased the skin microbiota diversity in the same
animal model.
Antibiotics 2021, 10, 124 17 of 29
Figure 8. Relationship of microbiota disturbance with developing diseases in different systems.
9. Endolysins and Antibiotics
The increased difficulty in treating antibiotic-resistant bacterial infections has created
the need for novel antimicrobial treatment options, which can be used as stand-alone
therapeutics or as a complement to antibiotics [137]. Research endeavors over the years
have raised strong recommendations for the synergetic approach to bacterial treatment
via endolysin–antibiotics combination. Early research work by Beveridge and colleagues
describe the role of Gram-negative bacteria outer membrane in shielding bacterial peptido-
glycan cell wall from exogenous treatment [138]. This work paved the way for subsequent
research works, which devised methods to breach the outer membrane protective mech-
anism [138]. In ensuring that the bacterial outer membrane barrier was no hindrance to
the exogenous lytic action of endolysin, Thumeepak et al. deployed the combined effect of
endolysin and antibiotic therapy in the treatment of multi-drug resistant strains of Gram-
negative Acinetobacter baumanii [139]. The study revealed elevated levels of antibacterial
activity with the combined administration of endolysin LysABP-01 and the antibiotic col-
istin, compared to either of the treatments alone [139]. Colistin, also known as Polymyxin
E, contains positively charged molecules that interact with negatively charged phosphates
of the cell membrane and displace divalent cations (Ca2+ and Mg2+), which contribute
to outer membrane instability. This interaction results in damage to the outer membrane
and leakage of cellular components causing eventual cell death [140]. The membrane
destabilizing activity of the antibiotics is then exploited by LysABP-01 to promote access
towards the cell wall target. The combination therapy was very successful, as there was
a significant increase in antibacterial activity, with growth inhibition rate reaching up to
100%. There was a considerable reduction in the minimum inhibitory concentrations (MIC)
of LysABP-01 by 32-fold and that of colistin by 8-fold, which allowed for lesser doses of
the two agents to be administered for treatment.
This approach has been proven to be equally effective in the treatment of Gram-
positive strains of Vancomycin-intermediate Staphylococcus aureus (VISA), through the com-
bined use of anti-Staphylococcal endolysin MV-L (derived from novel Staphylococcus aureus
bacteriophage ØMR11) in combination with glycopeptide antibiotics such as vancomycin
or teicoplanin [141]. Individually, MV-L at 50 U concentration and vancomycin at 4 µg/mL
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concentration showed weak suppression of Mu50 VISA strain growth rate. In contrast, the
simultaneous administration of the agents (12.5–50 U of MV-L and 4 µg/mL of vancomycin)
lysed the Mu50 cells to a greater extent. This synergy was also confirmed in broth culture,
with a predicted 100-fold decrease in colony-forming units per millimeter for the combined
treatments [141]. Authors attributed the synergy observed to the partial degradation of the
thickened bacterial cell wall by the MV-L endolysin, which allowed glycopeptide access to
sites close to the cell membrane.
In a similar study conducted by Kim et al. the anti-Staphylococcal effect of phage
endolysin SAL200 combined with standard-of-care (SOC) antibiotics such as nafcillin
and vancomycin was examined [142]. The study assessed in vitro bactericidal activity
and subsequent in-vivo activity using murine and Galleria mellonella infection models.
There was a significant decrease in the antibiotics’ minimum inhibitory concentration
(MIC) and S. aureus concentration in both assays. The study revealed the effectiveness of
SAL200 in restoring the sensitivity of nafcillin and vancomycin antibiotics at the brink of
resistance [142]. A lower bacterial density was reported in the splenic and blood tissues in
the murine model treated with a combination of SAL200 and SOC antibiotics, compared
with SAL200 treatment only. Galleria mellonella larvae infected with methicillin-resistant
and methicillin-susceptible strains of Staphylococcus aureus were treated with SAL200 and
SOC antibiotics at 96-h post-infection time, which resulted in an increased survival rate for
both strains. Overall, such results validate the synergetic relationship between SAL200 and
SOC antibiotics, both in vitro and in-vivo.
Letrado et al. demonstrated the synergetic effect of Cpl-711 endolysin and commonly
used antibiotics such as amoxicillin, levofloxacin, vancomycin, and cefotaxime in the
treatment of multi-drug resistant strains of Streptococcus pneumoniae [143]. The resulting
minimum inhibitory concentration indices revealed a robust synergetic relationship when
endolysin Cpl-711 was combined with amoxicillin and cefotaxime. The group suggested
that a plausible explanation for the synergism observed was the breakdown of the peptido-
glycan cell wall by antibiotics, which resulted in increased susceptibility to endolysins; a
mechanism quite similar to that earlier described by Rashel et al. [141].
A study conducted by Becker et al. highlighted the synergetic role of endolysin Lys K and
lysostaphin, a bacteriocin secreted by Staphylococcus simulans in killing Staphylococcus aureus [144].
Both antibacterial agents, which had been initially proven as effective in the treatment
of multi-drug resistant S. aureus strains in two separate studies were successfully com-
bined using a checkboard assay [145,146]. The pattern of cleared wells indicating growth
inhibition confirmed greater antimicrobial strength in combined use. To support this,
individually, each agent had MIC values of <30%; 18% for lysostaphin and <16% and
33% for Lys K endolysin for S. simulans and S. aureus, respectively. The overall fractional
inhibitory concentration (FIC) of 0.449 ± 0.069 on the other hand, however, suggests a
robust synergetic relationship [144].
In a more recent study conducted by Kashani et al., cysteine/histidine-dependent
amidohydrolase/peptidase (CHAP) and amidase, which are catalytic domains of endolysin
Lys K, were synergistically combined with vancomycin in the treatment of methicillin-
resistant Staphylococcus aureus (MRSA). The calculated FIC index (∑) revealed an 8-fold
reduction in the MIC value of vancomycin due to the synergistic effect of both agents using
a two-fold dilution [137].
Overall, the lytic action of antibiotics on bacterial cell wall peptidoglycan and the
consequent increase in endolysin susceptibility is believed by many to be the basis of
endolysin–antibiotics synergy, and this has been experimentally substantiated in studies
detailed in this review [141,143]. The evidence presented in these studies affirms the role
of endolysin–antibiotic synergy in improving therapeutic efficacy, as shown in a marked
decrease in antibiotic minimum inhibitory concentration. This, of course, would translate
to a reduction in antibiotics dosage administration. The remarkable results of the above
studies present high hopes in antibacterial treatment, as it becomes progressively evident
that the war against antimicrobial resistance requires a more inclusive approach, combining
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novel knowledge in endolysin research with conventional antibiotic use. The empirical
pieces of evidence from these studies are undeniable; they, however, would require human
clinical trials before they can be fully adopted as standard care practice.
10. Formulation and Administration Routes
To perform a successful administration of any therapeutic agent to the target site of
infection, there are some issues to be considered, including the administration route and
suitable delivery systems that maintain the treatment’s stability and activity [70]. Currently,
the administration of phage-derived enzymes can be applied via different routes including
injections (intravenous, and intraperitoneal), topical applications (creams, ointments, and
gels), transnasal, vaginal, and oral delivery systems [147]. Table 1 summarizes the different
endolysin administration routes and the targeted pathogenic bacteria.
The oral route of phage endolysins has the challenge to preserve the enzymatic activity
due to harsh gastric proteolytic enzymes and acidic pH. It is intended that the encapsu-
lation of phage proteins could provide a protective strategy to solve this problem [148].
Based on an initial human phase study of SAL200, the endolysin has proven to be safe
and effective besides causing mild adverse effects such as fatigue and headaches [21].
Information was obtained on the pharmacokinetics and pharmacodynamics of the product
upon intravenous injection in human subjects [67]. SAL200 is the first endolysin-based
therapeutic formulation with a recombinant form of phage endolysin SAL-1 (rSAL-1) [21].
This phage endolysin has in turn been derived from the bacteriophage SAP-1, which
infects several Staphylococci strains such as MRSA and vancomycin-resistant S. aureus
(VRSA) [18,149].
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Table 1. Selection of some endolysins and their administration routes.
Target Pathogen Phage Enzyme (Endolysin) Activity (Mode of Action) Administration Route References
Streptococcus pneumoniae
Cp1 Cpl-1 Muramidase Intravenous, nasal, oral, aerosols,and Intraperitoneal [17,150–154]
Dp-1 Pal Amidase Nasal and oral [50,155]
CP-7 Cpl-7 Muramidase Immersion [156,157]
Streptococcus pyogenes C1 PlyC Amidase Oral, nasal [16]
MGAS5005 prophage PlyPy Endopeptidase Intraperitoneal [158]
Streptococcus agalactiae NCTC11261 PlyGBS Endopeptidase and Muramidase Intravaginal, oral and intranasal [159]
SK1249 prophage PlySK1249 Amidase and endopeptidase Intraperitoneal [160]
MRSA
GH15 LysGH15 Amidase and endopeptidase Intravenous and Intraperitoneal [123,161]
MR11 MV-L Amidase and endopeptidase Intraperitoneal, nasal [141]
K LysK Amidase and endopeptidase Intraperitoneal [162]
SAP-1 SAL-1 Amidase and endopeptidase Intravenous [18]
phiSH2 prophage phiSH2 Amidase and endopeptidase Intraperitoneal [162]
phiP68 P68 Amidase and endopeptidase Intraperitoneal [162]
phiWMY LysWMY Amidase and endopeptidase Intraperitoneal [162]
phi80α 80αLyt2 Amidase and endopeptidase Intraperitoneal [162]
phi11 phi11 Amidase and endopeptidase Intraperitoneal [162]






Muramidase Oral and topical [79]
P. aeruginosa phage PlyPa03 Muramidase Topical [163]
P. aeruginosa phage PlyPa91 Muramidase Intranasal [163]
Acinetobacter baumannii
RL-2015 PlyF307 Muramidase Intraperitoneal and Topical [164]
SS3e LysSS Muramidase Intraperitoneal [165]
Bacillus anthracis γ-phage PlyG Amidase Intraperitoneal [93]
Enterococcus faecalis E. faecalis phage IME-EF1 LysIME-EF1 Endopeptidase Intraperitoneal [166]
E. faecalis phage EF-P10 LysEF-P10 Endopeptidase Intraperitoneal [167]
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11. Insights into the Clinical Trials of Engineered Endolysins
Recent advances in the sequencing of phage genomes have ignited the application of
endolysins as antimicrobials [45,168]. Endolysins, when applied to Gram-positive bacteria,
cause immediate results. In Gram-negative bacteria, the peptidoglycan layer (susceptible
layer) is protected by a less permeable outer membrane. Various strategies have been
adopted to address this issue, including the use of outer membrane permeabilizers such as
EDTA, gallic acid, and thymol in combination with endolysins in Gram-negative bacteria
to provide significant results [169]. permeablilizer
Endolysins combined with fusion peptides (lipopolysaccharide destabilizing peptides)
also promote the uptake of endolysin through the outer membrane in Gram-negative bacte-
ria. Artilysin® Art-175 (LYSANDO AG, Liechtenstein) is very effective against multidrug-
resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii [170]. It is made by
fusing the antimicrobial sheep myeloid peptide (29 amino acids) with endolysin KZ144 [79].
Modification of endolysins by molecular engineering techniques also improves the
lytic activity of an enzyme. Endolysins can have two types of domain structure i.e., globular
(Gram-negative bacteria) and modular (mainly Gram-positive bacteria). The modular
structure comprises N-terminal enzymatically active domain (EAD) and C-terminal cell
wall-binding domain (CBD) linked together by short, flexible regions. N-terminal serves
the purpose of enzymatic hydrolysis, and C-terminal is for substrate recognition [68].
Studies have shown that deletion or shortening of C-terminal CBD results in enhanced
lytic activity [171].
Both phages as well as isolated and bioengineered endolysins assure the therapeu-
tic potential against pathogenic bacteria. Endolysins have a broader host range than
phages [172], and still, due to their specificity, they only target specific pathogenic bacteria
without causing damage to microflora. Until now, no case of endolysin resistance has been
reported. This is because their target layer (peptidoglycan layer) is highly important for
the viability of bacteria and any mutation can lead to serious damage to bacteria [65].
Preclinical and clinical trials for therapeutic endolysins are in progress. Endolysins
(SAL200, CF-301, and P128) against S. aureus have reached the clinical trials (Table 2). Most
of these studies involving endolysins are targeting different routes of infections caused by
S. aureus [20].
Table 2. List of endolysins in human clinical trials.
Endolysin Study Phase Clinical Trials Identifier Status
CF-301
Safety, Efficacy, and Pharmacokinetics of CF-301 vs.
Placebo in Addition to Antibacterial Therapy for
Treatment of S. aureus Bacteremia




To evaluate safety and to explore the efficacy of a
single intravenous dose of N-Rephasin®SAL200
(3 mg/kg)
IIa NCT03089697 Ongoing trial
P-128
Safety & Efficacy of an Antibacterial Protein
Molecule Applied Topically to the Nostrils of
Volunteers and Patients
II NCT01746654 Completed
12. Challenges in Clinical Trials
Despite the remarkable qualities, some challenges need to be addressed. in vitro
studies are carried out using exponential phase bacterial cells where the endolysins have
shown excellent efficiency. Studies have shown that stationary phase cells are less suscep-
tible to endolysins due to peptidoglycan maturation [160]. Modifications occur during
acetylation/deacetylation of glycan chains; peptide amidation is responsible for resistance
against endolysins in both Gram-positive and Gram-negative bacterial cells [3].
Unwanted immune response to endolysins decreases their efficiency inside the human
body or causes anaphylaxis [173]. Using traditional mouse models, studies reported
the unreliable immunogenicity of endolysins in humans. During preclinical and clinical
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trials of SAL200, antibodies were produced in varying degrees in rats, dogs, monkeys,
and humans [67]. More trials are needed to understand the immunogenic nature of
endolysins. For endolysin bioengineering, X-ray crystallography is performed for the
structural characterization of these enzymes. However, difficulty in crystal formation of
endolysin is also a considerable challenge [68].
13. Conclusions and Future Perspectives
Due to the rise in multi-drug resistance bacterial infections across the globe, endolysins
as a novel therapeutic approach has received significant attention. Endolysins are an
attractive option as they show lytic potential against numerous bacterial species of concern
within veterinary and human medicine and show advantages within the agricultural and
biotechnology sector. Additionally, endolysins show promising advances against biofilm
formation. Interestingly, the recent exploration of resistance, safety, immunogenicity, and
the synergy with antibiotics has advanced the research of endolysins further.
Endolysins are the best alternative therapeutic approach to cure and treat multi-drug
resistant bacteria. Up to now, many endolysins are reported which show good results in
treating antibiotic-resistant bacteria. However, endolysin also has some challenges. En-
dolysins show good efficacy to treat Gram-positive bacteria, but due to Gram-negative bac-
terial outer membrane barrier, it shows less activity to treat Gram-negative bacteria [42,174].
Another limitation of endolysin is its short in-vivo half-life, due to the production of cy-
tokines’ inflammatory response, and the neutralizing antibodies against it. Endolysin
provokes an immune response when it is used systematically, so due to immune response,
it loses its enzymatic lytic activity in-vivo [133,175,176].
New strategies are needed to develop universal chimeric lysin, to cross the Gram-
negative bacterial outer membrane barrier, and to overcome these immunological responses
against endolysin. While endolysins are proving to be advantageous as novel therapeutics,
further research is required to consider their formulation and engineerability towards
clinical trials.
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